A medical device startup, first noticed by the UC Davis Institute for Innovation and Entrepreneurship, NeVap Inc., has received Food and Drug Administration clearance for the Aspire Subglottic Suction Endotracheal tube, a breathing tube designed to help improve the health of critically ill patients.
The Aspire Subglottic Suction Endotracheal tube is designed to remove fluids that contain bacteria and viruses that cause deadly Ventilator Associated Pneumonias (VAP). Cases of VAP affect upwards of 250,000 Americans each year and treatment costs average $40,000 per case.
While all previous commercial breathing tubes utilize only one (1) suction port that can become compromised due to tissue involvement, the NeVap Aspire breathing tube utilizes twenty four (24) unique suctioning points to maximize pathogen removal and safeguard critically ill patients that require mechanical ventilation.
For Benjamin Wang MD, inventor and chief medical officer of NeVap Inc, who first noticed this problem while treating ICU patients, FDA clearance represents a great opportunity to improve healthcare.
“Ventilator Associated Pneumonias continue to be deadly and significantly under-reported in the American Healthcare system. Clearance of the Aspire breathing tube means that help is on the way for millions of the sickest patients in modern medicine today” Wang said.
Wang received his B.S. in Biochemistry and Molecular Cellular Biology from UC Davis and feels a strong connection with the campus.
NeVap Inc plans to start offering the Aspire as early as March to a select few academic institutions. The Aspire will be offered to other institutions on a rolling basis.
Nevap Wins the UC Davis Big Bang Competition